Day: March 16, 2026

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

Written by Customer Service on March 16, 2026. Posted in Public Companies.

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive...

Azucar Minerals Ltd. Announces Change of Name to Mustang Minerals Limited

Written by Customer Service on March 16, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) — Azucar Minerals Ltd. (TSX-V: AMZ; OTCQB: AXDDF) (“Azucar” or the “Company”) announces that it has changed its name to “Mustang Minerals Limited” (the “Name Change”) and will trade under the new stock symbol “MMX” on the TSX Venture Exchange (the “TSXV”). At the opening of the markets on March 18, 2026, the Company’s common shares will commence trading on the TSXV under the new name Mustang Minerals Limited and the new stock symbol “MMX” for the TSXV and “MMXLF” on the OTCQB. The new CUSIP number assigned to the Company’s shares following the Name Change is 62819M102 (ISIN: CA62819M1023). The Name Change was approved by a resolution of the Board of Directors of the Company on March 4, 2025. In connection with the Name Change, the Company altered its Notice of Articles...

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Written by Customer Service on March 16, 2026. Posted in Public Companies.

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that Babar K. Rao, MD, FAAD, an internationally recognized academic dermatologist and Principal Investigator of the SKNJCT-003 Phase 2 clinical study, will join the Company’s leadership team during a business update webcast on March 26, 2026 at 11:30 a.m. Eastern time. The SKNJCT-003 study represents a randomized, double-blind Phase 2 clinical trial designed to rigorously...

SiriusPoint Announces Creation of Global P&C Programs and London Market Specialty Divisions

Written by Customer Service on March 16, 2026. Posted in Public Companies.

HAMILTON, Bermuda, March 16, 2026 (GLOBE NEWSWIRE) — SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), a specialty underwriter, has today announced changes to its business structure as part of the next phase of the Company’s evolution. SiriusPoint will now operate through four business areas, including three globally focused P&Ls: Global P&C Programs, Global Reinsurance, Global Accident & Health, and a London Market Specialty division, which includes Lloyd’s. SiriusPoint will combine its existing North America and International Programs businesses into one single Global P&C Programs division, which will be led by Patrick Charles, Global Head of P&C Programs. The new division reflects the Company’s commitment to the programs space, further strengthening its offering to clients and distribution...

Auction result of Treasury Bills – RIKV 26 0618 – RIKV 26 0916

Written by Customer Service on March 16, 2026. Posted in Public Companies.

Series RIKV 26 0618 RIKV 26 0916Settlement Date 03/18/2026 03/18/2026Total Amount Allocated (MM) 27,850 13,350All Bids Awarded At (Price / Simple interest) 98.157 / 7.347 96.469 / 7.240Total Number of Bids Received 22 21Total Amount of All Bids Received (MM) 47,850 39,850Total Number of Successful Bids 14 7Number of Bids Allocated in Full 14 7Lowest Price / Highest Simple Interest Allocated 98.157 / 7.347 96.469 / 7.240Highest Price / Lowest Simple Interest Allocated 98.194 / 7.197 96.491 / 7.193Lowest Price / Highest Simple Interest Allocated in Full 98.157 / 7.347 96.469 / 7.240Weighted Average of Successful Bids (Price/Simple Interest) 98.178 / 7.262 96.476 / 7.225Best Bid (Price / Simple Interest) 98.194 / 7.197 96.491 / 7.193Worst Bid (Price / Simple Interest) 98.134 / 7.441 96.328 / 7.540Weighted...

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

Written by Customer Service on March 16, 2026. Posted in Public Companies.

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved therapies Patent protection extends into 2038 QTORIN™ rapamycin has previously been granted European Orphan Drug Designation for the treatment of microcystic lymphatic malformations, potentially providing 10 years of market exclusivity in the European Union upon approval There are currently no approved therapies in the European Union for microcystic lymphatic malformations WAYNE, Pa., March 16, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing...

Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer

Written by Customer Service on March 16, 2026. Posted in Public Companies.

WINTER PARK, Fla., March 16, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced the appointment of Christine Plummer, former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer of Streamex. In this role, Ms. Plummer is expected to oversee the Company’s global finance organization, including financial reporting, regulatory compliance, and financial operations as Streamex continues expanding its institutional platform and launching tokenized commodity products. Henry McPhie, Co-Founder & CEO of Streamex said, “Christine brings a combination of deep traditional finance experience and leadership in digital asset infrastructure. We believe...

Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial

Written by Customer Service on March 16, 2026. Posted in Public Companies.

New randomized controlled trial to evaluate dose-dependent effects of oral THC on anxiety and stress using Avicanna’s proprietary capsules TORONTO, March 16, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the initiation of new Phase I randomized, double-blinded, placebo-controlled, dose-finding clinical trial (“Trial ”) led by researchers at the University of Calgary’s Cumming School of Medicine. Study Overview The Trial is led by Dr. Leah Mayo, Assistant Professor, and supported by Dr. Matthew Hill, Professor at the University of Calgary. This single site, randomized, double-blind, placebo-controlled crossover trial...

Signing Day Sports and BlockchAIn Provide Update on Expected Ticker Symbol Transition and Common Stock Trading Schedule

Written by Customer Service on March 16, 2026. Posted in Mergers And Acquisitions.

Signing Day Sports Common Stock Expected to Continue Trading on NYSE American Under “SGN” Through March 16, 2026 BlockchAIn Inc. Common Stock Expected to Begin Trading Under “AIB” on March 17, 2026 at 9:30 a.m. EDT SCOTTSDALE, Ariz. and NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) — Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN) and BlockchAIn Digital Infrastructure, Inc. (“BlockchAIn Inc.”), together with One Blockchain LLC (“BlockchAIn LLC” and, together with BlockchAIn Inc., “BlockchAIn”), today provided an update regarding their expected ticker symbol transition and common stock trading schedule in connection with their previously announced business combination, which was approved by the Company’s stockholders on March 13, 2026. Upon the closing of the previously announced business combination,...

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Written by Customer Service on March 16, 2026. Posted in Earnings Releases And Operating Results.

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced business updates and reported financial results for the fiscal year 2025. In 2025, Annovis achieved a significant milestone in its clinical development program with the initiation of a pivotal Phase 3 clinical trial in early AD. The year was largely dedicated to the activation of clinical sites and the enrollment of participants across the United States. The Company also reported encouraging data from both its previous Alzheimer’s and Parkinson’s programs, demonstrating a potential disease-modifying...

Day: March 16, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals